 |
|
|
|
|
Diabetes and Obesity: AMP-Activated Protein Kinase (AMPK)
 | | | | | | | 5’-AMP-activated protein kinase (AMPK), a trimeric enzyme in mammals, consists of a catalytic a subunit (63 kDa) and the non-catalytic b and g subunits. AMPK is activated by increases in the cellular AMP/ATP ratio caused by metabolic stress that either interferes with ATP production or accelerates ATP consumption. AMP affects AMPK by a direct allosteric activation thereby making it a poor substrate for dephosphorylation. AMPK stimulates pathways that are linked to increased energy production, such as glucose transport and fatty acid oxidation. On the other hand, it switches off the energy consuming pathways, such as lipogenesis, protein synthesis, and gluconeogenesis. | | | | | | | Activators |
|
|
|
| AICA-Riboside |
123040 |
| AICA-Riboside, 5′-Phosphate |
123041 |
| AMPK Activator |
171256 |
| 1,1-Dimethylbiguanide, Hydrochloride |
317240 |
| Leptin, Human, Recombinant, E. coli |
429700 |
| Leptin, Mouse, Recombinant, E. coli |
429705 |
|
| | | | Antibodies |
|
|
|
|
|
| Anti-AMPKa-2 Rabbit pAb |
IB, IP |
bovine, human, rat |
ST1089 |
| Anti-LKB1 (120-160) Rabbit pAb |
IB |
human |
ST1092 |
|
| | | | Inhibitors |
|
|
|
| AMPK Inhibitor, Compound C |
171260 |
| InSolution™ AMPK Inhibitor, Compound C |
171261 |
| (-)-Deguelin, Mundulea sericea |
252740 |
| STO-609 |
570250 |
|
| | | | | | Related Resources | | Inhibitor Resource | | | | | |
|
 |
|
|
